B.P. Marsh & Partners PLC is an asset management business based in the UK. B.P. Marsh & Partners shares (BPM.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. B.P. Marsh & Partners employs 17 staff and has a trailing 12-month revenue of around £17.6 million.
|Latest market close||N/Ap|
|52-week range||131.7436p - 278p|
|50-day moving average||267.1212p|
|200-day moving average||246.7305p|
|Wall St. target price||320p|
|Dividend yield||0.02p (0.83%)|
|Earnings per share (TTM)||37.4p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing B.P. Marsh & Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of B.P. Marsh & Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
B.P. Marsh & Partners's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, B.P. Marsh & Partners shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
B.P. Marsh & Partners's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £13.9 million.
The EBITDA is a measure of a B.P. Marsh & Partners's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£17.6 million|
|Operating margin TTM||78.95%|
|Gross profit TTM||£12.9 million|
|Return on assets TTM||6.3%|
|Return on equity TTM||9.85%|
|Market capitalisation||£99.5 million|
TTM: trailing 12 months
Dividend payout ratio: 600% of net profits
Recently B.P. Marsh & Partners has paid out, on average, around 600% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), B.P. Marsh & Partners shareholders could enjoy a 0.83% return on their shares, in the form of dividend payments. In B.P. Marsh & Partners's case, that would currently equate to about 0.02p per share.
B.P. Marsh & Partners's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 25 June 2020 (the "ex-dividend date").
Over the last 12 months, B.P. Marsh & Partners's shares have ranged in value from as little as 131.7436p up to 278p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while B.P. Marsh & Partners's is 0.8212. This would suggest that B.P. Marsh & Partners's shares are less volatile than average (for this exchange).
B.P. Marsh & Partners PLC is a private equity and venture capital firm specializing in investments in early stage, developmental capital/acquisition capital, startups, management buyouts, management buyins, and hive offs. The firm does not invest in insurance companies or businesses exposed to principle risk. It prefers to invest in the financial services sector with a focus on insurance intermediaries; asset managers; independent financial advisors; wealth and fund managers, specialist advisory and consultancy firms and professional consultants. The firm prefers to invest in United Kingdom, Europe, North America and Internationally. It typically invests up to £5 million ($6.28 million). The firm makes equity investments and is able to provide debt funding, which is in addition to, and not instead of, an equity investment. It takes minority stakes ranging from 20 percent to 40 percent and prefers to exit its investments through a trade sale or an IPO. The firm insists to appoint a non-executive board of director in its portfolio companies and also makes follow-on investments. B.P. Marsh & Partners PLC was founded in 1990 and is based in London, United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.